Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals (NASDAQ: LXRX) announced its participation in the upcoming 3rd Annual H.C. Wainwright BioConnect Investor Conference. The company's management will engage in a fireside chat scheduled for Tuesday, May 20, at 9:30 a.m. ET at the Nasdaq World Headquarters in New York City. Investors and interested parties can access both the live presentation and its replay through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX) ha annunciato la sua partecipazione al 3° Annuale H.C. Wainwright BioConnect Investor Conference. Il management dell'azienda parteciperà a una conversazione informale prevista per martedì 20 maggio alle 9:30 ET presso la sede centrale del Nasdaq a New York City. Investitori e interessati potranno seguire la presentazione in diretta e rivederla successivamente nella sezione Eventi del sito web delle relazioni con gli investitori di Lexicon all'indirizzo https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX) anunció su participación en la próxima 3ª Conferencia Anual de Inversores H.C. Wainwright BioConnect. La dirección de la empresa participará en una charla informal programada para el martes 20 de mayo a las 9:30 a.m. ET en la sede mundial de Nasdaq en la ciudad de Nueva York. Los inversores y las partes interesadas podrán acceder tanto a la presentación en vivo como a su repetición a través de la sección de Eventos en el sitio web de relaciones con inversores de Lexicon en https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX)는 다가오는 제3회 연례 H.C. Wainwright BioConnect 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 5월 20일 화요일 오전 9시 30분 ET에 뉴욕시 나스닥 본사에서 예정된 비공식 대화에 참여할 예정입니다. 투자자 및 관심 있는 분들은 Lexicon의 투자자 관계 웹사이트 https://investors.lexpharma.com/의 이벤트 섹션을 통해 생중계 및 재방송을 시청할 수 있습니다.
Lexicon Pharmaceuticals (NASDAQ : LXRX) a annoncé sa participation à la 3e conférence annuelle H.C. Wainwright BioConnect pour investisseurs. La direction de l'entreprise participera à une discussion informelle prévue le mardi 20 mai à 9h30 ET au siège mondial du Nasdaq à New York. Les investisseurs et parties intéressées pourront accéder à la fois à la présentation en direct et à sa rediffusion via la section Événements du site web des relations investisseurs de Lexicon à l'adresse https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX) gab bekannt, dass es an der bevorstehenden 3. jährlichen H.C. Wainwright BioConnect Investorenkonferenz teilnehmen wird. Das Management des Unternehmens wird an einem Fireside-Chat teilnehmen, der für Dienstag, den 20. Mai, um 9:30 Uhr ET im Nasdaq-Welt-Hauptquartier in New York City geplant ist. Investoren und Interessierte können sowohl die Live-Präsentation als auch die Wiederholung über den Bereich Events auf der Investor-Relations-Website von Lexicon unter https://investors.lexpharma.com/ verfolgen.
- None.
- None.
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET.
The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
When is Lexicon Pharmaceuticals (LXRX) presenting at the H.C. Wainwright BioConnect Conference?
Where can I watch Lexicon Pharmaceuticals' (LXRX) H.C. Wainwright conference presentation?
What type of presentation will LXRX give at the H.C. Wainwright conference?
Where is the 3rd Annual H.C. Wainwright BioConnect Investor Conference being held?
